Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays.
Cordova C, Syeda M, Corless B, Wiggins J, Patel A, Kurz S, Delara M, Sawaged Z, Utate M, Placantonakis D, Golfinos J, Schafrick J, Silverman J, Jain R, Snuderl M, Zagzag D, Shao Y, Karlin-Neumann G, Polsky D, Chi A. Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays. Journal Of Clinical Oncology 2019, 37: 2026-2026. DOI: 10.1200/jco.2019.37.15_suppl.2026.Peer-Reviewed Original ResearchCell-free circulating tumor DNADroplet digital PCR assayDroplet digital PCRCtDNA levelsTERT mutationsPharmacodynamic biomarkersPlasma cell-free circulating tumor DNATERT promoter hotspot mutationsTERT promoter mutationsPromoter hotspot mutationsFFPE tumor samplesUnresected glioblastomaC228TPreoperative MRIIDH-wildtypeTumor DNADigital PCR assayIDHwt glioblastomasClinical stabilityTumor mutationsClinical outcomesClinical associationsGlioblastoma patientsHotspot mutationsTumor samples